News and Trends 25 Oct 2016 The First Peanut Allergy Therapy might soon hit the Shelves DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […] October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 This Diagnostic Tool beats the Standard for Respiratory Infection Tests Curetis is drastically reducing the time required to test for severe infectious diseases. The newest incorporation is expected early next year and could soon substitute the hospital standards. Curetis is a German biotech that commercializes diagnostic technologies for infectious diseases. After a very successful IPO last year, the company is advancing its Unyvero platform for fast diagnostics. The […] October 25, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 Meet the Cyborg Bacteria that Culture Themselves What if you could program your bacteria to grow in any pattern you fancy? Researchers from ETH Zurich can, and this is huge news for the Biotech Industry! Scientists from ETH Zurich have developed a fully automated system that can precisely control bacterial growth using light. What’s more, unlike other prototypes, this system can adjust to any […] October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored 25 Oct 2016 7 Considerations for Commercializing a New Drug So you have exciting science, but do you know if it will be a commercial success? Ask the drug development and commercialization experts, who have turned the pharma analytics and consultancy industry on its head! We sat down with Mirador Analytics, to talk about bringing a drug from the clinic to the market. They are […] October 25, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 A €103M Target to Reduce Drug Dosage with a Slow-Release Tech Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 Here comes the First-ever Combination Therapy for Multiple Sclerosis Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […] October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2016 The Colours of Biotech: Who’s Doing What in the European Ecosystem in an Infographic Happy Monday! Our colleague, Justine, has put together a wonderful infographic to map out which European biotech companies are making moves in which field, from health to agrotech to medtech. Its vivid colours will surely brighten your day – take a look-see below! Justine is pursuing a PhD at the Heinrich Heine Universität in Düsseldorf after obtaining […] October 24, 2016 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2016 Meet the Bioartist that wants to Replace all your Furniture with… Fungi! Can you imagine a future where everything in your daily life is made out of fungi..? It’s actually not such a stretch idea: this bioartist is showing the world all these microorganisms can do. Maurizio Montalti is an artist that uses fungi to build his own furniture and homeware. In 2010, he founded Officina Corpuscoli in Amsterdam […] October 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 New Partnership comes to the Rescue in Neurological Diseases Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 It’s time to Modernize Anesthetics! Meet the PAIONeers We travel from Finland back to the heart of Europe to visit the beautiful sights of Aachen. The citizens are starting to turn on the heat and get ready for its famous Christmas markets, while we visit our Biotech of the week, Paion. City: Aachen, Germany Founded: 2000 Employees: 35 Financial Data: €163M market cap + €10M in […] October 21, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […] October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 German Record-deal Antiviral drug Succeeds in Phase III AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email